FDA reviews diabetic and HIV medications

Mar 27, 2008

The U.S. Food and Drug Administration has announced safety reviews of the FDA-approved medications Regranex Gel, Ziagen and Videx.

The FDA said study data suggests there might be an increased risk of death from cancer in diabetic patients using Regranex (becaplermin) Gel to treat leg and foot ulcers.

The FDA said it was also studying data that indicate a higher risk of heart attack in patients infected with the human immunodeficiency virus who take Ziagen (abacavir) or Videx (didanosine) as part of their drug therapy.

Until all three reviews are completed, the FDA said health care professionals should evaluate the potential risks and benefits of each drug with their patients.

Copyright 2008 by United Press International

Explore further: Lilly psoriasis drug fares well in late-stage test

add to favorites email to friend print save as pdf

Related Stories

Calcium makes for an environmentally friendly pickle

Jul 08, 2014

George Washington had a collection of 476 kinds of pickles. To prevent scurvy, Christopher Columbus stocked pickles on the Niña, Pinta, and Santa Maria. Julius Caesar, believing pickles to be invigorating, ...

DARPA-funded DEKA arm system earns FDA approval

May 12, 2014

DARPA launched the Revolutionizing Prosthetics program with a radical goal: gain U.S. Food and Drug Administration (FDA) approval for an advanced electromechanical prosthetic upper limb with near-natural contro ...

Recommended for you

Lilly psoriasis drug fares well in late-stage test

2 hours ago

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

New US restrictions on painkiller to take effect

15 hours ago

The federal government is finalizing new restrictions on hundreds of medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the U.S.

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

User comments : 0